|
|
|
|
|
|
|
|
|
20.04.26 - 16:54
|
BMY Stock: Analysts See 16% Upside and a Strong Buy (24/7 Wall St.)
|
|
|
Bristol-Myers Squibb (NYSE:BMY) trades at $60.17 as of writing. The 24/7 Wall St. Price Target is $70.12, implying upside of 16.51% over the next 12 months. The 24/7 Wall St. model rating is buy, with a high (90%) confidence level. Metric Value Current Price $60.17 24/7 Wall St. Price Target $70.12 Upside/Downside +16.51% Model Rating ... BMY Stock: Analysts See 16% Upside and a Strong Buy...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.04.26 - 14:03
|
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux.
“This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnerships, and reflects the continued promise of our tumor-activated platforms,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “The nomination of a development candidate highlights our ability to translate platform insights into differentiated therapeutics in col...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
